Aquestive Therapeutics Inc (OQ:AQST)

Mar 25, 2024 08:00 am ET
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the...
Mar 22, 2024 09:31 am ET
Thinking about buying stock in Akebia Therapeutics, Boeing, Aquestive Therapeutics, General Electric, or Canoo?
NEW YORK, March 22, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, BA, AQST, GE, and GOEV.
Mar 21, 2024 09:31 am ET
Thinking about buying stock in SoundHound AI, Aquestive Therapeutics, Akebia Therapeutics, Kaival Brands, or Lufax?
NEW YORK, March 21, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOUN, AQST, AKBA, KAVL, and LU.
Mar 19, 2024 09:49 pm ET
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the...
Mar 19, 2024 04:01 pm ET
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that...
Mar 14, 2024 05:23 pm ET
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Mee
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today released positive topline clinical data from...
Mar 05, 2024 05:05 pm ET
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today reported financial results for the fourth...
Feb 21, 2024 08:00 am ET
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that...
Feb 15, 2024 08:00 am ET
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a...
Jan 30, 2024 08:00 am ET
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will...
Jan 19, 2024 08:31 am ET
Thinking about buying stock in Coffee Holding Co., Aquestive Therapeutics, Snowflake Inc, Mesoblast, or Modular Medical?
NEW YORK, Jan. 19, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JVA, AQST, SNOW, MESO, and MODD.
Jan 10, 2024 08:31 am ET
Thinking about buying stock in American Lithium, Nkarta, Riot Platforms, Aquestive Therapeutics, or Nvni Group?
NEW YORK, Jan. 10, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMLI, NKTX, RIOT, AQST, and NVNI.
Dec 05, 2023 08:31 am ET
Thinking about buying stock in Mongodb, Aquestive Therapeutics, Sovos Brands, Travere Therapeutics, or Ibio Inc?
NEW YORK, Dec. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MDB, AQST, SOVO, TVTX, and IBIO.
Dec 05, 2023 08:00 am ET
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that...
Nov 10, 2023 08:00 am ET
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that...
Nov 06, 2023 04:37 pm ET
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today reported financial results for the third quarter...
Nov 02, 2023 08:00 am ET
Aquestive Therapeutics Completes $45 Million Debt Refinancing
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the refinancing of its existing debt...
Oct 31, 2023 08:00 am ET
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that...
Oct 09, 2023 08:00 am ET
Aquestive Therapeutics Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided a business update on its...
Sep 20, 2023 09:31 am ET
Thinking about buying stock in Novo Integrated Sciences, Archer Aviation, Cemtrex, Aquestive Therapeutics, or Murphy Canyon Acquisition Corp?
NEW YORK, Sept. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVOS, ACHR, CETX, AQST, and MURF.
Sep 20, 2023 09:04 am ET
Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on the...
Sep 11, 2023 08:00 am ET
Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Aug 23, 2023 08:00 am ET
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives,...
Aug 07, 2023 04:01 pm ET
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today reported financial results for the...
Aug 02, 2023 08:00 am ET
Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives,...
Aug 01, 2023 09:31 am ET
Thinking about buying stock in Rivian Automotive, VERSES AI, Sunworks, Aquestive Therapeutics, or Mind Medicine?
NEW YORK, Aug. 1, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIVN, VRSSF, SUNW, AQST, and MNMD.
Jul 27, 2023 07:00 am ET
Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Jul 25, 2023 04:01 pm ET
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Jul 25, 2023 08:00 am ET
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Jul 06, 2023 08:00 am ET
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Jun 29, 2023 08:42 am ET
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
May 31, 2023 08:00 am ET
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Finding
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
May 02, 2023 04:31 pm ET
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today reported financial results for the...
Apr 26, 2023 08:00 am ET
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the management...
Apr 20, 2023 08:00 am ET
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Apr 18, 2023 08:00 am ET
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Mar 29, 2023 08:30 am ET
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has expanded its...
Mar 07, 2023 04:01 pm ET
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today reported financial results for the...
Mar 01, 2023 08:00 am ET
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the management...
Feb 22, 2023 08:00 am ET
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Feb 21, 2023 08:00 am ET
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI)
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Jan 06, 2023 08:00 am ET
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Dec 22, 2022 08:00 am ET
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today...
Nov 29, 2022 08:00 am ET
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today the publication of a crossover food effect...
Nov 15, 2022 08:00 am ET
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today that the management team will participate in the two...
Nov 09, 2022 04:33 pm ET
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, will present three abstracts recapping positive data from its...
Nov 01, 2022 04:01 pm ET
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, today reported financial results for the third quarter ended...
Oct 27, 2022 09:05 am ET
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today a transaction to license Sympazan® (clobazam) oral...
Oct 27, 2022 09:00 am ET
Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.
Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced a transaction to acquire an exclusive license for Sympazan® (clobazam) oral film...
Oct 24, 2022 08:00 am ET
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today that the United States District Court for the...
Oct 19, 2022 08:00 am ET
Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, today announced that it will report results for third quarter ended...
Oct 11, 2022 08:00 am ET
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, today announced positive written feedback from the U.S. Food and...
Sep 28, 2022 08:00 am ET
Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has...
Sep 27, 2022 09:31 am ET
Thinking about buying stock in Kiora Pharmaceuticals, X4 Pharmaceuticals, Ayala Pharmaceuticals, Aquestive Therapeutics, or Alaunos Therapeutics?
NEW YORK, Sept. 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KPRX, XFOR, AYLA, AQST, and TCRT.
Sep 27, 2022 07:00 am ET
Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced positive topline...
Sep 12, 2022 04:01 pm ET
Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the establishment of a...
Sep 07, 2022 09:31 am ET
Thinking about buying stock in Aquestive Therapeutics, Alaunos Therapeutics, Ardelyx, IVERIC Bio, or Nio?
NEW YORK, Sept. 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AQST, TCRT, ARDX, ISEE, and NIO.
Aug 31, 2022 04:02 pm ET
Aquestive Therapeutics to Participate in Two Investor Conferences in September
Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management...
Aug 31, 2022 08:00 am ET
Aquestive Therapeutics Receives FDA Tentative Approval for Libervant™ (diazepam) Buccal Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the U.S. Food &...
Aug 18, 2022 09:31 am ET
Thinking about buying stock in Curis, bluebird bio, Nerdy, Sientra, or Aquestive Therapeutics?
NEW YORK, Aug. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRIS, BLUE, NRDY, SIEN, and AQST.
Aug 15, 2022 09:37 am ET
Thinking about buying stock in Ironsource, Helbiz, Liquidia, Twin Vee Powercats, or Aquestive Therapeutics?
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IS, HLBZ, LQDA, VEEE, and AQST.
Aug 10, 2022 04:50 pm ET
Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space
Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of...
Aug 02, 2022 04:02 pm ET
Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today reported financial results for...
Jul 26, 2022 08:00 am ET
Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management...
Jul 20, 2022 08:00 am ET
Aquestive Therapeutics to Report Second Quarter 2022 Financial Results and Recent Business Highlights on August 2 and Host Conference Call on August 3 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it will report...
Jul 11, 2022 08:00 am ET
Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST-109 Epinephrine Oral Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced positive topline...
Jun 15, 2022 04:22 pm ET
Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced positive topline...
Jun 08, 2022 04:01 pm ET
Aquestive Therapeutics, Inc. Announces Closing of $8.5 Million Registered Direct Offering
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it has closed its...
Jun 07, 2022 08:00 am ET
Aquestive Therapeutics to Participate in JMP Securities Life Sciences Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management...
Jun 06, 2022 08:30 am ET
Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it has entered...
May 17, 2022 04:01 pm ET
Aquestive Therapeutics Announces CEO Transition
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that Keith Kendall,...
May 10, 2022 08:00 am ET
Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management...
May 04, 2022 09:31 am ET
Thinking about buying stock in Immutep, Brickell Biotech, Indonesia Energy, TG Therapeutics, or Aquestive Therapeutics?
NEW YORK, May 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMMP, BBI, INDO, TGTX, and AQST.
May 03, 2022 05:40 pm ET
Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today reported financial results for...
Apr 18, 2022 08:00 am ET
Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that it will report...
Apr 13, 2022 08:00 am ET
Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has entered into a...
Apr 12, 2022 08:00 am ET
Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced positive topline...
Mar 29, 2022 05:49 am ET
(AQST Alert) Long Term Holders of Aquestive Contact Johnson Fistel for Information Regarding Investigation
Johnson Fistel, LLP is investigating potential breaches of fiduciary duty/or violations of federal and/or state law on behalf of Aquestive Therapeutics, Inc. (NASDAQ: AQST) against certain of its officers and directors. Earlier this year, a class...
Mar 17, 2022 09:31 am ET
Thinking about buying stock in Aquestive Therapeutics, Mullen Automotive, Ring Energy, Destination XL, or Enservco?
NEW YORK, March 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AQST, MULN, REI, DXLG, and ENSV.
Mar 17, 2022 08:00 am ET
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that the U.S. Food and...
Mar 08, 2022 04:56 pm ET
Aquestive Therapeutics Reports Full Year 2021 Results Exceeding Revenue and EBITDA Guidance
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today reported financial results for the...
Mar 03, 2022 08:00 am ET
Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives,  announced the execution...
Feb 28, 2022 08:33 pm ET
Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, presented a late breaking poster...
Feb 25, 2022 07:00 am ET
Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced positive topline...
Feb 24, 2022 09:26 pm ET
Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced the opening of its...
Feb 22, 2022 08:00 am ET
Aquestive Therapeutics to Report Fourth Quarter and Year End 2021 Financial Results and Recent Business Highlights on March 8 and Host Conference Call on March 9 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company improving and advancing medicines to solve patients’ problems with current standards of care in order to better their lives with transformative products, announced today that it...
Jan 13, 2022 11:50 am ET
Gainey McKenna & Egleston Investigates Potential Claims On Behalf of Investors of Aquestive Therapeutics, Inc. (AQST)
Gainey McKenna & Egleston announces that it is investigating whether the directors and/or officers of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) breached their fiduciary duties of loyalty, good faith and candor and...
Jan 07, 2022 08:00 am ET
Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will...
Dec 21, 2021 06:22 am ET
SHAREHOLDER ALERT: Robbins LLP Investigates Aquestive Therapeutics, Inc. (AQST) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) to determine whether certain Aquestive officers and directors violated securities laws and breached their fiduciary duty to the Company. Aquestive is a specialty pharmaceutical company that develops products to address un
Dec 20, 2021 10:49 pm ET
Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that, regarding the review of...
Dec 18, 2021 10:20 am ET
Did You Acquire (AQST) Before December 2, 2019? Should Aquestive Therapeutics Management be Held Accountable for Investors Losses? Contact Johnson Fistel
Johnson Fistel, LLP is investigating potential claims on behalf of Aquestive Therapeutics, Inc. (NASDAQ: AQST) against certain of its officers and directors. Earlier this year, a class action complaint was filed against Aquestive Therapeutics....
Dec 17, 2021 08:00 am ET
Aquestive Therapeutics Added to NASDAQ Biotechnology Index
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that NASDAQ has added...
Dec 13, 2021 08:00 am ET
Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Tri
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported that it has received a written...
Nov 29, 2021 08:30 am ET
SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its novel antifungal,...
Nov 17, 2021 08:00 am ET
Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will...
Nov 02, 2021 04:30 pm ET
Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the third...
Oct 25, 2021 08:31 am ET
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephri
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced positive topline data from...
Oct 14, 2021 08:00 am ET
Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results...
Oct 06, 2021 05:59 pm ET
Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal A
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has reached an...
Sep 29, 2021 04:30 pm ET
IntelGenx and Aquestive Therapeutics Partner with Leading Men’s Health Company to Market Tadalafil Oral Films in the U.S.
IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (“ED”) and benign prostatic hyperplasia (BPH) (the...
Sep 07, 2021 08:00 am ET
Aquestive Therapeutics to Participate in Three Investor Conferences in September
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will...
Aug 09, 2021 08:00 am ET
Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant™ Related Capital Under Current Debt Agreement
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has reached an...
Aug 06, 2021 08:00 am ET
Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will...
Aug 03, 2021 05:54 pm ET
Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year Revenue Guidance
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the...
Jul 21, 2021 08:00 am ET
Aquestive Therapeutics to Report Second Quarter 2021 Financial Results and Recent Business Highlights on August 3 and Host Conference Call on August 4 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results...
Jul 19, 2021 09:29 am ET
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug...
Jun 24, 2021 08:00 am ET
Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today the resubmission of its New...
Jun 23, 2021 08:30 am ET
SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that it will present a commercial launch update for its recently...
Jun 21, 2021 09:15 am ET
Aquestive Therapeutics Announces Leadership Transition of Chief Financial Officer
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that A. Ernest (Ernie) Toth,...
Jun 09, 2021 08:30 am ET
Aquestive Therapeutics to Participate in JMP Securities and BMO Capital Market Investor Conferences
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will...
May 11, 2021 09:27 am ET
Aquestive Therapeutics to Participate in 2021 RBC Capital Markets Global Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will...
May 04, 2021 07:53 pm ET
Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the first...
Apr 30, 2021 11:00 am ET
AQST Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 30, 2021
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aquestive securities between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Apr 28, 2021 09:27 pm ET
Aquestive Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Aquestive Therapeutics, Inc. (NASDAQ: AQST) investors that acquired shares between December 2, 2019 and September 25, 2020. Investors have until April...
Apr 28, 2021 11:33 am ET
AQST FINAL DEADLINE ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important April 30 Deadline in Securities Class
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April 30,...
Apr 28, 2021 11:00 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
The Law Offices of Frank R. Cruz reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ:
Apr 26, 2021 11:00 am ET
AQST Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 30, 2021
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aquestive securities between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Apr 26, 2021 11:00 am ET
DEADLINE ALERT for UAVS, IQDAX, IQDNX, and AQST: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 24, 2021 12:30 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 23, 2021 08:02 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors With Losses Over $100K to Secure Counsel Before Important April 30 Deadline in Securities Class Action – AQST
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April...
Apr 23, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutics, Inc....
Apr 21, 2021 02:59 pm ET
AQST ALERT: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against  Aquestive Therapeutics, Inc. – AQST
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). To join the class...
Apr 21, 2021 10:00 am ET
MGI, AQST & VLDR Class Action Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 21, 2021 09:18 am ET
Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Host Conference Call on May 5 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results...
Apr 20, 2021 11:00 am ET
DEADLINE ALERT for UAVS, IQDAX, IQDNX, and AQST: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 19, 2021 01:00 pm ET
DEADLINE ALERT for IQDAX, AQST, VLDR, REGI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 14, 2021 11:04 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 13, 2021 11:00 am ET
DEADLINE ALERT for UAVS, IQDAX, IQDNX, and AQST: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 12, 2021 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutics, Inc....
Apr 12, 2021 10:00 am ET
MGI, AQST & VLDR Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 10, 2021 05:00 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action – AQST
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April 30,...
Apr 09, 2021 12:00 pm ET
DEADLINE ALERT for IQDAX, AQST, VLDR, REGI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 06, 2021 11:00 am ET
DEADLINE ALERT for UAVS, IQDAX, IQDNX, and AQST: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 03, 2021 12:48 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important April 30 Deadline in Securities Class Action – AQST
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April...
Apr 01, 2021 12:30 pm ET
DEADLINE ALERT for IQDAX, AQST, VLDR, REGI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 31, 2021 12:28 pm ET
AQST DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against  Aquestive Therapeutics, Inc. – AQST
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). To join the class...
Mar 30, 2021 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutics, Inc....
Mar 30, 2021 08:00 am ET
DEADLINE ALERT for UAVS, IQDAX, IQDNX, and AQST: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 29, 2021 01:03 pm ET
AQST INVESTOR LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Mar 26, 2021 05:30 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April 30, 2021 lead plaintiff deadline.
Mar 25, 2021 11:30 am ET
DEADLINE ALERT for IQDAX, AQST, VLDR, REGI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 25, 2021 08:30 am ET
Aquestive Therapeutics Successfully Demonstrates Repeatable and Predictable Oral Sublingual Film Administration of Epinephrine
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, will provide later this morning an in-depth...
Mar 24, 2021 12:16 pm ET
AQST DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Aquestive Therapeutics, Inc. – AQST
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). To join the class...
Mar 24, 2021 11:00 am ET
DEADLINE ALERT for UAVS, IQDAX, IQDNX, and AQST: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 23, 2021 04:13 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April...
Mar 22, 2021 10:17 am ET
AQST INVESTOR LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Mar 18, 2021 11:30 am ET
DEADLINE ALERT for IQDAX, AQST, VLDR, REGI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 17, 2021 11:00 am ET
DEADLINE ALERT for UAVS, IQDAX, IQDNX, and AQST: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 17, 2021 10:12 am ET
AQST INVESTOR LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Mar 16, 2021 03:33 pm ET
AQST DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Aquestive Therapeutics, Inc. – AQST
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). To join the class...
Mar 12, 2021 12:30 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ:
Mar 12, 2021 11:25 am ET
DEADLINE ALERT for UAVS, IQDAX, IQDNX, and AQST: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 12, 2021 10:00 am ET
AQST Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) and certain of its officers, on behalf of...
Mar 10, 2021 01:00 pm ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
Law Offices of Howard G. Smith reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) securities between December 2, 2019 and September 25, 2020, inclusive (the “Class Per
Mar 10, 2021 10:00 am ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – AQST
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April 30,...
Mar 09, 2021 05:49 pm ET
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the...
Mar 08, 2021 04:46 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – AQST
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April 30, 2021 lead plaintiff deadline.
Mar 08, 2021 12:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ:
Mar 08, 2021 11:10 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ:
Mar 06, 2021 11:19 am ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – AQST
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020,...
Mar 05, 2021 12:07 pm ET
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Aquestive Therapeutics, Inc.– AQST
Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) from December 2, 2019 through September 25, 2020, inclusive (the “Class Period”). The lawsuit seeks to...
Mar 05, 2021 11:30 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) securities between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). Aquestive investors have until April 30, 2021 to
Mar 05, 2021 10:00 am ET
AQST Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) and certain of its officers, on behalf of...
Mar 05, 2021 07:00 am ET
Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will host a virtual...
Mar 04, 2021 12:31 pm ET
SHAREHOLDER ALERT: Robbins LLP Announces That Aquestive Therapeutics, Inc. (AQST) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Aquestive Therapeutics, Inc. (NASDAQ: AQST) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between December 2, 2019 and September 25, 2020. Aquestive is a spe
Mar 04, 2021 11:00 am ET
The Law Offices of Frank R. Cruz Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ:
Mar 04, 2021 09:42 am ET
AQUESTIVE THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP notifies investors that a securities class action lawsuit has been filed in the United States District Court
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) in  United States District Court for the District...
Mar 04, 2021 09:09 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Conta
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aquestive Therapeutics, Inc. (“Aquestive” or “the Company”) (NASDAQ:
Mar 04, 2021 09:00 am ET
Notice of Lead Plaintiff Deadline for Shareholders in the Aquestive Therapeutics, Inc. Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of New Jersey on behalf of purchasers of Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). The case is captioned Lewakowski v. Aquestive Therapeutics, Inc., No. 21-cv-03751, and is assigned to Judge Brian R. Martinotti. The Aquestive class action lawsuit charges Aquestive and certain of its executives with violations of the Securities Exchange Act of 1934.
Mar 03, 2021 06:30 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ:
Mar 03, 2021 05:27 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) investors concerning the Company’s possible violations of federal securities laws.
Mar 03, 2021 01:47 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aquestive Therapeutics, Inc. (“Aquestive” or “the Company”) (NASDAQ:
Mar 03, 2021 10:33 am ET
AQST BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – AQST
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 30, 2021.
Mar 03, 2021 10:16 am ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (“Aquestive”) (NASDAQ: AQST) in the United States District Court for the District of New Jersey on behalf of those who purchased or...
Mar 02, 2021 04:02 pm ET
AQST INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Aquestive Therapeutics, Inc. (“Aquestive” or the...
Mar 01, 2021 10:27 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Aquestive Therapeutics, Inc. and Certain Officers - AQST
NEW YORK, March 1, 2021 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and certain of its officers. The class action, filed in United States District Court for the District of New Jersey, and docketed under 21-cv-03751, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Aquestive securities between December 2, 2019 and September 25, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caus
Feb 25, 2021 07:30 am ET
Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that the Food and Drug...
Feb 17, 2021 07:30 am ET
Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results...
Feb 09, 2021 07:30 am ET
Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie...
Jan 28, 2021 07:30 am ET
Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Mark...
Jan 21, 2021 07:30 am ET
Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment
JERSEY CITY, N.J. and WARREN, N.J., Jan. 21, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S. rights to commercialize EXSERVAN™ (riluzole), an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis (ALS).
Jan 07, 2021 07:30 am ET
Aquestive Therapeutics Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today provided an update on recent...
Jan 04, 2021 07:30 am ET
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will...
Dec 16, 2020 08:00 am ET
Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that John Maxwell, Senior...
Nov 25, 2020 09:15 am ET
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will...
Nov 23, 2020 07:00 am ET
Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today receipt of the first...
Nov 18, 2020 04:01 pm ET
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today the completion of a Type A...
Nov 04, 2020 04:30 pm ET
Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the third...
Nov 03, 2020 07:00 am ET
Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has entered a royalty...
Oct 14, 2020 07:30 am ET
Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results...
Sep 25, 2020 05:38 pm ET
Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug...
Aug 20, 2020 07:30 am ET
Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including An
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today the initiation of a Phase 1...
Aug 10, 2020 07:30 am ET
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug...
Aug 04, 2020 04:01 pm ET
Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date Approaches
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today reported financial results for...
Jul 28, 2020 04:15 pm ET
Aquestive Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management will present...
Jul 15, 2020 07:57 am ET
Aquestive Therapeutics to Announce Second Quarter Financial Results and Recent Business Highlights on Aug 4 and Host Conference Call on Aug 5 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results...
Jun 29, 2020 07:00 am ET
Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has submitted an...
Jun 16, 2020 08:00 am ET
Aquestive Therapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management will present...
Jun 04, 2020 05:05 pm ET
Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that due to the public health...
May 22, 2020 11:40 am ET
Thinking about buying stock in Xeris Pharmaceuticals, Aquestive Therapeutics, Navidea Biopharmaceuticals, Sundial Growers, or Hexo Corp?
NEW YORK, May 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XERS, AQST, NAVB, SNDL, and HEXO.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.